space
space

Get in Touch

spacer(91)-20-49072626
Saturday
Apr 18, 2015
subscribe
You are here article details
 

US FDA’s Alert On Wockhardt: Much Ado About Nothing?

| 5/30/2013 9:02 PM Thursday

Pharma giant Wockhardt has received a strong setback after the US FDA sounded an alert on its Waluj manufacturing facility, after which the stock was hammered by more than 25 per cent in just two trading sessions. The market, however, seems to be overreacting to these developments. Shrikant Akolkar tells us more.

One of the worst things to happen to any stock is for it to get hit by factors which are apparently serious but on deeper exploration seem to be routine. This happens chiefly due to investors’ knee-jerk reaction to news flows which creates humongous negativity around it. One company which has recently been hit by this syndrome is Wockhardt.

We had recommended Wockhardt in DSIJ Vol. 28, Issue # 9 (dated 21 April, 2013) in our cover story ‘Cherry Picking’. The scrip was severely hammered following the recent US FDA alert on its manufacturing facility located in Waluj, Aurangabad district of Maharashtra. In just two trading sessions alone (May 23 and 24, 2013) it lost more than 25 per cent in value. Currently, the stock is down 35 per cent from where we had recommended it. Investors who have acted on our advice would surely be jittery in the wake of such a slide in the stock’s price. What should their future course in this counter be? Should one sell and book losses or wait out the depression? Here are the answers that you would be looking out for.

To start with, the hammering of the stock was a knee-jerk reaction arising out of fears fuelled by a particular event. This fear was accentuated by many other factors that were external to the company. The principal factor among these was the developments in Ranbaxy earlier in the same week.

Ranbaxy, the pharma company now owned by Daichhi Sankyo, pleaded guilty before the United States Department of Justice on compliance related issues in two of its manufacturing facilities. This was in any case weighing heavily on pharma stocks. The alert on Wockhardt’s Waluj facility came immediately after this, and dampened the sentiment on the stock.

What is worth noting is that Ranbaxy had ignored earlier malpractices, the consequences of which it had to bear. Wockhardt, however, had invited the US FDA team to audit its new injectables unit at Waluj. This is what differentiates between the two companies.

Find More Articles on: DSIJ Magazine, Special Report, Stock Recommendations, Fundamental Picks, Product, Large Cap

«« First « Previous |1 2 | Last ››

Related Readings

Top 10 companies with Lowest Foreign Institutional Investors (FIIs) Holding in BSE 100 Companies

DSIJ.in Exclusive

LatestMost PopularMarket Action

Market In Bears Grip, Nifty Touches 8600 Mark

This was the third consecutive session that the Indian markets closed below its previous close. The sectoral indices like Healthcare, Bankex and Auto were hammered badly and broke all the vital supports.   Mid-Caps and Small-Caps also tanked and fell by more than 150 points each. The Nifty continued with the negative momentum and was down by 100 points and closed at 8606 while Sensex was down by 223 points and closed at 28442 in today’s trade.

Index Trends And Stocks In Action April 17, 2015

Indian equity market extended its fall for second consecutive session led by constant selling pressure in the Pharma, Banking and Capital goods stock. Nifty after forming Bearish Engulfing candlestick on Wednesday followed it will a bearish candlestick.

Market Is Likely To Open Weak

Asian shares edged up in early trade on Friday, on track to score weekly gains and shrugging off a languid performance on Wall Street after another set of lackluster U.S. economic data. SGX Nifty is trading at flat. Indian market is likely to open weak. Crisil, Delta Corp, RS Software and Reliance Ind would be reporting fourth quarter earnings today.

Taxation On Redemption Of Gold Bond

Jayesh Dadia, Chartered Accountant

Breaking News

Muthoot Group Steps Into Home Loan Sector

The Muthoot Group that was majorly into gold loan portfolio has entered into the home loan segment with the launch of ‘Muthoot Homefin’ in Kochi. The housing loan vertical forms Muthoot’s 17th division. Muthoot Homefin will extend housing fi nance to enable customers to fulfill their dream to build/acquire a residential space of their own. Muthoot Homefin services for the customers were launched from April 15 onwards. Muthoot Homefin will offer housing loans from Rs 1 lakh to Rs 500 lakh at interest rates from 10.20 per cent p.a onwards for periods up to 30 years. Repayment of the amount shall be through equated monthly installments and on diminishing balance basis. Loan Against Property (LAP) will be offered in the range of  Rs 10 lakh to Rs 5 crore for a period up to 15 years with interest rate of 13 per cent onwards.

Dollar Index: GOING BACK AND FORTH

The uncertainty over the US’ economy and other global concerns has put the Dollar Index under pressure but it is likely to remain supported for the coming months

Naveen Mathur, Associate Director - Commodities & Currencies, Angel Commodities Broking (P) Ltd.

Kerbside

The recommendations provided in this column are taken from different market sources such as brokers, analysts, dealers and investment strategists, etc. These recommendations may not be backed by strong fundamentals. Dalal Street Investment Journal may or may not subscribe to these recommendations.

MULTI-ASSET CLASS FUNDS: A CLOSER LOOK

Should multi-asset class funds be a part of your portfolio considering it has both pros and cons?

Hemant Rustagi, CEO, Wiseinvest Advisors

FTP 2015-20: QUEST TO PUT INDIA ON GLOBAL TRADING MAP

The new FTP, according to the government, will help synchronize Indian trade with the new global scenario. Amit Bhanot takes a closer look at how these transformations will create a more positive scenario

An objective to touch export target of USD 900 billion by 2020.

Scrips that are being issued for basic custom duty under this would be freely transferrable for any kind of use.

Subsidies are now passé and the whole global trading space will change with competition being the key factor

Stock Recommendations For Your Portfolio

The scrips in this column have been recommended with a short-term investment horizon in mind and carry high risk. Therefore, investors are advised to take into account their risk appetite before investing, as fundamentals may or may not back the recommendations.

DSIJ Breakfast News

Start your day with DSIJ Breakfast Roundup, wind up with DSIJ Market Roundup. Register now to get the day’s market outlook, global cues, economic trends, top corporate news delivered straight to your inbox.

mail to

Start your day with DSIJ Breakfast Roundup, wind up with DSIJ Market Roundup. Register now to get the day’s market outlook, global cues, economic trends, top corporate news delivered straight to your inbox.

mail to  *
 *
 *
 *
 *
 *
Content

WE VALUE YOUR FEEDBACK

(* No Research/Stock Queries)
Name :
Email ID :
Cell Number :
Message :